XML 25 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)
¥ in Thousands, $ in Thousands
Ordinary shares
CNY (¥)
shares
Ordinary shares
USD ($)
shares
Treasury stock
CNY (¥)
Treasury stock
USD ($)
Additional paid-in capital
CNY (¥)
Additional paid-in capital
USD ($)
Accumulated other comprehensive loss
CNY (¥)
Accumulated other comprehensive loss
USD ($)
Accumulated deficit
CNY (¥)
Accumulated deficit
USD ($)
Noncontrolling interests
CNY (¥)
Noncontrolling interests
USD ($)
Contingently redeemable noncontrolling Interest
CNY (¥)
CNY (¥)
USD ($)
Balance at Dec. 31, 2020 ¥ 105   ¥ (8)   ¥ 1,840,026   ¥ (46,429)   ¥ (2,456,649)   ¥ 150,110   ¥ 2,913,675 ¥ (512,845)  
Balance, shares at Dec. 31, 2020 | shares 130,251,685 130,251,685                          
Net loss                 (271,427)   (251,245)     (522,672)  
Other comprehensive income     1       16,933             16,934  
Accretion of contingently redeemable noncontrolling interests                 (549,194)   182,087   367,107 (367,107)  
Share-based compensation         14,680                 14,680  
Contribution from noncontrolling interest                     1,500     1,500  
Contribution from contingently redeemable noncontrolling interests                         400,000    
Acquisition of additional shares of non-wholly owned subsidiaries         81,846           355,184     437,030  
Redemption of 15% equity of Global Medical Imaging (Hong Kong) Limited held by GE Healthcare Pte. Ltd. to reduce minority shareholders' equity                     (4,581)     (4,581)  
Balance at Dec. 31, 2021 ¥ 105   (7)   1,936,552   (29,496)   (3,277,270)   433,055   3,680,782 (937,061)  
Balance, shares at Dec. 31, 2021 | shares 130,251,685 130,251,685                          
Net loss                 (489,661)   (279,329)     (768,990)  
Other comprehensive income             1,730             1,730  
Accretion of contingently redeemable noncontrolling interests                     3,680,782   ¥ (3,680,782) 3,680,782  
Share-based compensation         (5,919)                 (5,919)  
Investment in equity instrument(Note 14)                     45,115     45,115  
Balance at Dec. 31, 2022 ¥ 105   (7)   1,930,633   (27,766)   (3,766,931)   3,879,623     2,015,657  
Balance, shares at Dec. 31, 2022 | shares 130,251,685 130,251,685                          
Net loss                 (297,658)   (233,363)     (531,021) $ (74,795)
Other comprehensive income             (37,653)             (37,653)  
Disposal partial interest of a subsidiary         (18,110)           18,110        
Capital injection from a noncontrolling interests         95,442           204,562     300,004  
Balance at Dec. 31, 2023 ¥ 105 $ 15 ¥ (7) $ (1) ¥ 2,007,965 $ 282,816 ¥ (65,419) $ (9,214) ¥ (4,064,589) $ (572,485) ¥ 3,868,932 $ 544,928   ¥ 1,746,987 $ 246,059
Balance, shares at Dec. 31, 2023 | shares 130,251,685 130,251,685